The development of carbon-based nanomaterials has extensively facilitated new discoveries in various fields. Carbon nanotube-based nanocomposites (CNT-based nanocomposites) have lately recognized as promising biomaterials for a wide range of biomedical applications due to their unique electronic, mechanical, and biological properties. Nanocomposite materials such as silver nanoparticles (AgNPs), polymers, biomolecules, enzymes, and peptides have been reported in many studies, possess a broad range of antibacterial activity when incorporated with carbon nanotubes (CNTs). It is crucial to understand the mechanism which governs the antimicrobial activity of these CNT-based nanocomposite materials, including the decoupling individual and synergistic effects on the cells. In this review, the interaction behavior between microorganisms and different types of CNT-based nanocomposites is summarized to understand the respective antimicrobial performance in different conditions. Besides, the current development stage of CNT-based nanocomposite materials, the technical challenges faced, and the exceptional prospect of implementing potential antimicrobial CNT-based nanocomposite materials are also discussed.

This study aims to synthesise zinc oxide nanoparticles with rutin (ZnO-R NPs) using a green synthesis approach and characterise the nanostructures for diverse biomedical applications. In this study, the optical and chemical properties of synthesised ZnO-R NPs were verified through Fourier transform infrared (FTIR) spectroscopy and ultraviolet-visible (UV-Vis) spectroscopy. The FTIR spectroscopy revealed a symmetric bending vibration peak of 460 cm⁻¹ for ZnO-R NPs, whereas UV-Vis spectroscopy showed a distinct absorption band at 395 nm. Moreover, the oval-shaped morphology of ZnO-R NPs was verified through scanning electron microscopy and transmission electron microscopy. The synthesised nanoformulation revealed a wurtzite structure with a crystallite size of 13.22 nm; however, the zeta potential value was recorded as −8.50 ± 0.46 mV for ZnO-R NPs. According to an antioxidant study, ZnO-R NPs demonstrated lower free-radical scavenging activity than pure rutin. The cytotoxicity study was conducted using a human breast cancer cell line (MCF-7). In vitro analysis verified that ZnO-R NPs exhibited significantly higher anticancer and microbial growth inhibition activities than standard ZnO NPs (ZnO Std NPs) and pure rutin. In addition, ZnO-R NPs revealed a significantly lower IC₅₀ value than the commercial ZnO Std NPs and pure rutin in MCF-7 cells (16.39 ± 6.03 μg/mL, 27 ± 0.91 μg/mL and 350 ± 30.1 μg/mL, respectively) after 48 h. However, synthesised ZnO-R NPs demonstrated no significant toxicity towards Artemia nauplii. These results highlight the synthesis of rutin-mediated ZnO NPs and their possible chemotherapeutic potential.

The development of new antibiotics is urgently needed to combat the threat of bacterial resistance. New classes of compounds that have novel properties are urgently needed for the development of effective antimicrobial agents. The extract of Cannabis sativa L. has been used to treat multiple ailments since ancient times. Its bioactivity is largely attributed to the cannabinoids found in its plant. Researchers are currently searching for new anti-infective agents that can treat various infections. Although its phytocannabinoid ingredients have a wide range of medical benefits beyond the treatment of infections, they are primarily associated to psychotropic effects. Different cannabinoids have been demonstrated to be helpful against harmful bacteria, including Gram-positive bacteria. Moreover, combination therapy involving the use of different antibiotics has shown synergism and broad-spectrum activity. The purpose of this review is to gather current data on the actions of Cannabis sativa (C. sativa) extracts and its primary constituents such as terpenes and cannabinoids towards pathogens in order to determine their antimicrobial properties and cytotoxic effects together with current challenges and future perspectives in biomedical application.

Vaccinations are vital as they protect us from various illness-causing agents. Despite all the advancements in vaccine-related research, developing improved and safer vaccines against devastating infectious diseases including Ebola, tuberculosis and acquired immune deficiency syndrome (AIDS) remains a significant challenge. In addition, some of the current human vaccines can cause adverse reactions in some individuals, which limits their use for massive vaccination program. Therefore, it is necessary to design optimal vaccine candidates that can elicit appropriate immune responses but do not induce side effects. Subunit vaccines are relatively safe for the vaccination of humans, but they are unable to trigger an optimal protective immune response without an adjuvant. Although different types of adjuvants have been used for the formulation of vaccines to fight pathogens that have high antigenic diversity, due to the toxicity and safety issues associated with human-specific adjuvants, there are only a few adjuvants that have been approved for the formulation of human vaccines. Recently, nanoparticles (NPs) have gain specific attention and are commonly used as adjuvants for vaccine development as well as for drug delivery due to their excellent immune modulation properties. This review will focus on the current state of adjuvants in vaccine development, the mechanisms of human-compatible adjuvants and future research directions. We hope this review will provide valuable information to discovery novel adjuvants and drug delivery systems for developing novel vaccines and treatments.